SOHO State of the Art Updates and Next Questions | Update on Tailoring Therapy in T Cell Lymphomas

Abstract

Peripheral T cell lymphomas are rare and heterogenous diseases with no clear curative options in the relapsed setting. Treatments based on paradigms for aggressive B cell lymphomas have yielded poor outcomes and there is an immense need for therapies that are directed towards PTCL. Understanding the biology and pathologic pathways for this group of diseases has allowed the development of more specific targeted therapies. The are initially evaluated in the relapsed setting with the hope that these agents will then be combined with more traditional lymphoma directed therapies for improved outcomes. This approach has also elucidated that PTCL subtypes differ in biology and treatments should be tailored depending accordingly.

Keywords: Brentuximab Vedotin; HDAC inhibitors; Hypomethylating agents; PI3 kinase inhibitor; Relapsed PTCL-.